RUBINSTEIN JULIE sold $709K of ADPT
RUBINSTEIN JULIE (President and COO) sold 23,762 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $29.82 ($28.87–$30.58, $0.71M total) across 5 trades over 2026-11-09 to 2026-11-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds modest negative pressure on ADPT, but the magnitude is limited.
Market read
A routine insider sale with modest size; likely limited short‑term impact on ADPT price.
What to watch
Potential upcoming clinical data releases or partnership announcements could offset the sell‑off impact.
Background
Form 4 filings disclose insider transactions; a sale of this size by a senior officer is routinely reported.
Ticker impact
President and COO Julie Rubinstein sold 23,762 shares of Adaptive Biotechnologies for $708,557, a disclosed Form 4 insider sale.
likely downward pressure as the market prices in the insider sell
A C‑suite insider sold nearly $0.71 M of stock under a 10b5‑1 plan; such sales often trigger short‑term selling pressure.
Market effects
Minimal impact on the broader biotech sector; isolated insider transaction.
U.S. market only; no regional ripple.
Low; limited to Adaptive Biotechnologies shareholders.
Counterpoint
The sale follows a pre‑arranged 10b5‑1 plan and may not reflect negative sentiment; the stock could remain stable.
Key entities
- CompanyAdaptive Biotechnologies Corp
Biotech firm focused on immune profiling and diagnostics.
- ExecutiveJulie Rubinstein
President and COO of Adaptive Biotechnologies.



